公开(公告)号：MX387728B

公开(公告)日：2025-03-18

申请号：MX2020004501

申请日：2012-12-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  FYFE GWEN ,  BUGGY JOSEPH J ,  ELIAS LAURENCE ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/437 ,  A61P35/00

Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.

公开(公告)号：MX380504B

公开(公告)日：2025-03-12

申请号：MX2016012396

申请日：2012-12-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  FYFE GWEN ,  BUGGY JOSEPH J ,  ELIAS LAURENCE ,  MODY TARAK D

IPC: A61K31/519 ,  A61P35/02

Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.

公开(公告)号：NZ753024A

公开(公告)日：2020-08-28

申请号：NZ75302411

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Disclosed is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) in the manufacture of a medicament for treating diffuse large B-cell lymphoma (DLBCL) in an individual in need thereof, wherein the medicament is formulated for administration of the compound once per day in an amount of about 560 mg, in a solid oral dosage form.

公开(公告)号：AU2017272271A1

公开(公告)日：2018-01-04

申请号：AU2017272271

申请日：2017-12-07

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/52 ,  A61K31/519 ,  A61P35/00

Abstract: USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.

公开(公告)号：CA3110966A1

公开(公告)日：2013-04-25

申请号：CA3110966

申请日：2012-10-19

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: G01N33/48 ,  A61K31/519 ,  A61P35/00

Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.

公开(公告)号：CA3022256A1

公开(公告)日：2011-12-08

申请号：CA3022256

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K9/48 ,  A61K39/395 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：CA3007788A1

公开(公告)日：2011-12-08

申请号：CA3007788

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K39/395 ,  A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：CA3007787A1

公开(公告)日：2011-12-08

申请号：CA3007787

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：NZ772688A

公开(公告)日：2022-09-30

申请号：NZ77268811

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Use of ibrutinib as an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), in the manufacture of a medicament for treating chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), wherein said medicament is to be administered in an oral dose of 420 mg of said inhibitor once per day until progression of the CLL or SLL or unacceptable toxicity; and lymphocytosis is not considered progression of the CLL or SLL.

公开(公告)号：AU2020202752B2

公开(公告)日：2022-04-07

申请号：AU2020202752

申请日：2020-04-24

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.